Dana-Farber Cancer Institute: Myelodysplastic Syndromes trials

The registry lists 24 Myelodysplastic Syndromes studies with Dana-Farber Cancer Institute as lead sponsor. 7 are open to participants now and 6 have results posted.

Phase 1 10Phase 2 5No phase 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable
• Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationRecruitingNCT06138587Phase 1
• Genomically Profiling, Collecting, Archiving and Distributing Hematologic Malignancy SpecimensRecruitingNCT04968834
• IS-free Treg HaploHCTRecruitingNCT04678401Phase 1
• A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell TransplantationRecruitingNCT04024761Phase 1
• SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)RecruitingNCT03113643Phase 1
• Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical OutcomeRecruitingNCT02269592
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDSCompletedNCT03660228Not applicableResults posted
• The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) StudyCompletedNCT02390414Results posted
• GVAX vs. Placebo for MDS/AML After Allo HSCTTerminatedNCT01773395Phase 2Results posted
• Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related DonorsCompletedNCT01323920Phase 2Results posted
• Deferoxamine for Iron Overload Before Allogeneic Stem Cell TransplantationTerminatedNCT00658411Not applicableResults posted
• Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I TrialTerminatedNCT03735446Phase 1
• Observational Study of Iron Overload in Stem Cell TransplantationCompletedNCT00954720
• Collection and Banking of Leukemia Cells MDS/AMLCompletedNCT00809367Not applicable
• Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell TransplantationCompletedNCT00809250Phase 1
• GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid MalignanciesCompletedNCT00426205Not applicable
• Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell TransplantCompletedNCT00376480Phase 1
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell TransplantationCompletedNCT00144703Phase 2
• Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell TransplantationCompletedNCT00144677Phase 2
• A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)CompletedNCT00136461Phase 2
• Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous LeukemiaCompletedNCT00136422Phase 1
• Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous TherapyCompletedNCT00005988Phase 1